# US 2023/0057665 A1 · Anti-il-1-beta antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0057665 A1
- Document ID: US20230057665A1
- Status: Published application
- Kind: A1
- Application number: 17/759,059
- Filed: 2021-01-19
- Published: 2023-02-23
- Earliest claimed: 2020-01-20
- Assignees: Eli Lilly and Company
- Applicants: Eli Lilly and Company
- Inventors: Wendy Loza HOBBS; Andrew Dixon SKORA
- Web page: https://patentgrep.com/patent/US20230057665A1

## CPC

- C07K 16/245: {IL-1}
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- G01N 33/575: for cancer
- G01N 33/6893: {related to diseases not provided for elsewhere}
- A61K 2039/505: {comprising antibodies}
- C07K 2317/21: from primates, e.g. man
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/74: Inducing cell proliferation
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G01N 2333/7155: for interleukins [IL]
- G01N 2800/32: Cardiovascular disorders
- G01N 2800/709: Toxin induced
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present disclosure provides human engineered IL-1 beta antibodies, cells and vectors comprising DNA encoding the same, and methods for producing the antibodies. In addition, the present disclosure provides the use of the human engineered IL-1 beta antibodies for the treatment of inflammatory diseases such as cardiovascular disease and cancer.

## Claims

### Claim 1

An antibody that binds human IL-1β protein comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH comprises heavy chain complementarity determining regions (HCDR) HCDR1, HCDR2, and HCDR3, and the VL comprises light chain complementarity determining regions (LCDR) LCDR1, LCDR2, and LCDR3, wherein
(SEQ ID NO:7)
the HCDR1 comprises AASGFTFSDHYMS,
(SEQ ID NO:8)
the HCDR2 comprises YISSSGSTIYYADSVKG,
(SEQ ID NO:9)
the HCDR3 comprises AREADSSGYYYVGVDV,
(SEQ ID NO:11)
the LCDR1 comprises RASQSISSYLN,
(SEQ ID NO:12)
the LCDR2 comprises YGASSDQS, and
(SEQ ID NO:13)
the LCDR3 comprises QQGYYFPPT.

### Claim 2 (depends on 1)

The antibody of claim 1, wherein the VH comprises SEQ ID NO:6 and the VL comprises SEQ ID NO:10.

### Claim 3 (depends on 1)

The antibody of claim 1, wherein the VH comprises SEQ ID NO:17 and the VL comprises SEQ ID NO:10.

### Claim 4 (depends on 1)

The antibody of claim 1, wherein the VH comprises SEQ ID NO:18 and the VL comprises SEQ ID NO:10.

### Claim 5 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a heavy chain (HC) comprising SEQ ID NO:2 and a light chain (LC) comprising SEQ ID NO:4.

### Claim 6 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a heavy chain (HC) comprising SEQ ID NO:15 and a light chain (LC) comprising SEQ ID NO:4.

### Claim 7 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a heavy chain (HC) comprising SEQ ID NO:16 and a light chain (LC) comprising SEQ ID NO:4.

### Claim 8 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a heavy chain (HC) comprising amino acids 2-449 of SEQ ID NO:2, and a light chain (LC) comprising SEQ ID NO:4.

### Claim 9 (depends on 1)

The antibody of claim 1, wherein the antibody comprises a HC consisting of SEQ ID NO:2 and an LC consisting of SEQ ID NO:4.

### Claim 10 (depends on 1)

The antibody of claim 1, wherein the antibody has a human IgG1 or IgG4 isotype.

### Claim 11 (depends on 10)

The antibody of claim 10, wherein the antibody has a human IgG4 isotype.

### Claim 12

A nucleic acid comprising a sequence encoding SEQ ID NO:2 or 4.

### Claim 13

A composition comprising
(a) a vector comprising a first nucleic acid sequence encoding SEQ ID NO:2 and a second nucleic acid sequence encoding SEQ ID NO:4; or
(b) a first vector comprising a nucleic acid sequence encoding SEQ ID NO:2 and a second vector comprising a nucleic acid sequence encoding SEQ ID NO:4.

### Claim 14

A cell comprising
(a) a vector comprising a first nucleic acid sequence encoding SEQ ID NO:2 and a second nucleic acid sequence encoding SEQ ID NO:4; or
(b) a first vector comprising a nucleic acid sequence encoding SEQ ID NO:2 and a second vector comprising a nucleic acid sequence encoding SEQ ID NO:4.

### Claim 15 (depends on 14)

The cell of claim 14, wherein the cell is a mammalian cell.

### Claim 16 (depends on 14)

A process of producing an antibody comprising culturing the cell of claim 14 under conditions such that the antibody is expressed and recovering the expressed antibody from the culture medium.

### Claim 17 (depends on 14)

An antibody produced by culturing the cell of claim 14 under conditions such that the antibody is expressed and recovering the expressed antibody from the culture medium.

### Claim 18 (depends on 1)

A pharmaceutical composition comprising the antibody of claim 1, and a pharmaceutically acceptable excipient, diluent or carrier.

### Claim 19 (depends on 1)

A method of treating inflammatory disease related to human IL-1β in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody of claim 1.

### Claim 20 (depends on 19)

The method of claim 19 wherein the inflammatory disease is Muckle Wells Syndrome (MWS), crypyrin-associated periodic syndrome (CAPS), neonatal-onset multisystem inflammatory syndrome (NOMIS), rheumatoid arthritis, systemic-onset juvenile idiopathic arthritis (soJIA), gout arthritis, chronic obstructive pulmonary disease (COPD), Type 1 diabetes, Type 2 diabetes, familial cold auto-inflammatory syndrome (FCAS), or age-related macular degeneration.

### Claim 21 (depends on 1)

A method of treating cardiovascular disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody of claim 1.

### Claim 22 (depends on 21)

The method of claim 21 wherein the cardiovascular disease is angina, myocardial infarction (MI), stroke, heart failure, or arrythmia.

### Claim 23 (depends on 1)

A method of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of the antibody of claim 1.

### Claim 24 (depends on 23)

The method of claim 23 wherein the cancer is non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), metastatic prostate cancer, low or intermediate risk myeloidoplastic leukemia, or localized kidney cancer.
